Ask AI
ProCE Banner Activity

KEYNOTE-355: Randomized, Placebo-Controlled Phase III of Pembrolizumab + Chemotherapy in Previously Untreated Metastatic TNBC (Final Results)

Conference Coverage
Slideset

Addition of pembrolizumab to chemotherapy improved both OS and PFS in patients with locally recurrent unresectable or metastatic triple-negative breast cancer with PD-L1 CPS ≥10.

Released: September 28, 2021

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc